Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-07868489
- Development stage
- Phase 2
- Lead developer
- Pfizer
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
PF-07868489 is an investigational recombinant human IgG1 monoclonal antibody developed by Pfizer for the treatment of pulmonary arterial hypertension (PAH). Its mechanism of action involves targeting and neutralizing bone morphogenetic protein 9 (BMP9, also known as GDF2), a member of the TGF-beta superfamily implicated in vascular remodeling and endothelial function. The drug is administered via subcutaneous injection and is currently being evaluated in Phase 1/2 clinical trials to assess its safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity profile, and preliminary efficacy in both healthy adults and patients with PAH[1][2][3][4][5][6][7][8].
- Other names
- anti-BMP9 antibodyanti-BMP-9 antibodyanti-BMP 9 antibody
02
Targets
BMP9 (Bone morphogenetic protein 9)
Beyond the preview
Go deeper on PF-07868489.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-07868489.